Core Modifications of GSK3335103 toward Orally Bioavailable αvβ6 Inhibitors with Improved Synthetic Tractability

已完结 20 由 LZI 发布于 2025/9/22 12:28:53

DOI:10.1021/acs.jmedchem.4c02051
作者：Heather F. Hryczanek, John Barrett, Tim N. Barrett, Glenn A. Burley, Rosa E. Cookson, Richard J. D. Hatley, Nicholas D. Measom, James A. Roper, James E. Rowedder, Robert J. Slack, Connor B. ?mieja, Si
文献类型：期刊论文
补充材料：只需要正文

其它数据库

Abstract：The αvβ6 integrin has been identified as a target for the treatment of fibrotic diseases, based on the role it has in activating TGF-β1, a protein implicated in the pathogenesis of fibrosis.

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Going offline to enhance memory during sleep